Description: Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.
Home Page: filament.health
4475 Wayburne Drive
Burnaby,
BC
V5G 4X4
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Benjamin Lightburn | Co-Founder, CEO & Chairman |
| Ms. Lisa Ranken | Chief Operating Officer |
| Mr. Ryan Moss | Chief Science Officer |
| Mr. Jonathan Conlin | Corporate Secretary & Director |
| Mr. Steven Nguyen CPA | Interim Chief Financial Officer |
| Ms. Anna Cordon | Vice President of Marketing & Communications |
| Mr. Jeff Fellows | Head of Regulatory |
| Andry Tjahyana | VP of Business Development |
| Sara Burke B.A., M.B.A. | Head of Global Partnerships |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6375 |
| Price-to-Sales TTM: | 2.1439 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |